FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

washington, D.C. 20048	,

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Evans John M.				Bea	Issuer Name and Ticker or Trading Symbol Beam Therapeutics Inc. [BEAM] Date of Earliest Transaction (Month/Day/Year)										licable) tor er (give tit		10% Othe	Owner er (specify	
(Last) (First) (Middle) C/O BEAM THERAPEUTICS INC.,					04/03/2023									below) below)					
238 MAIN STREET				4. If a	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02142														filed by (filed by N on		•			
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication													
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year	Exe) if ar	2A. Deemed Execution Da if any (Month/Day/)		Code	Transaction Code (Instr.		4. Securities Acqui Disposed Of (D) (In					5. Amount of Securities Beneficially Owned Following		ership Direct et (I) 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	Code V		ount	(A) or (D)	Price	e	Reported Transaction(s) (Instr. 3 and 4)					
Common Stock		04/03/2023				S ⁽¹⁾		5,	,161	D	\$30.31		1,124,472(2)		D				
Common Stock		04/04/2023			S ⁽¹			6,	493	D	\$29.0935(3)		1,117,979		D				
Common Stock														103,000		I		By John M. Evans, III 2018 Irrevocable Trust	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year)			Transaction Code (Instr. 8) S A A (// D O (I		5. Nu of Deriv Secu Acqu (A) o Dispo of (D) (Instr and 5	rities ired r osed . 3, 4	Expirat	Exercisable and ion Date Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivativ Securitie Benefici Owned Followin Reporte	ollowing eported ransaction(s)	10. Owners Form: Direct (I or Indire (I) (Instr	Beneficial Ownership cct (Instr. 4)	
				Code	v	(A)	(D)	Date Exercis	able	Expirat Date	Amoun or Numbe of Shares								

Explanation of Responses:

- 1. These shares of common stock were sold pursuant to a a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
- 2. Includes 480 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$28.81 to \$29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

By: /s/ Christine Bellon, Attorney-in-fact

** Signature of Reporting Person

04/05/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.